Richard A. Heyman - Dec 21, 2023 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Dec 21, 2023
Transactions value $
-$2,808
Form type
4
Date filed
12/26/2023, 07:29 PM
Previous filing
Dec 21, 2023
Next filing
Feb 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale -$91 -7 0% $13.00 147K Dec 21, 2023 Direct F1
transaction ELVN Common Stock Sale -$78 -6 -0.02% $13.00 29.3K Dec 21, 2023 See footnote F1, F2
transaction ELVN Common Stock Sale -$2.18K -168 -0.11% $13.00 147K Dec 22, 2023 Direct F1
transaction ELVN Common Stock Sale -$455 -35 -0.12% $13.00 29.2K Dec 22, 2023 See footnote F1, F2
holding ELVN Common Stock 37.4K Dec 21, 2023 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023.
F2 The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.
F3 The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.